Johnson and Johnson Merck Consumer Pharmaceuticals News
News on Johnson and Johnson Merck Consumer Pharmaceuticals continually updated from thousands of sources around the net.
Do You Know the Constitution Better Than Most Politicians?
Do you support affirmative action?
Sovaldi is approved to treat four different strains of hepatitis virus referred to as genotype 1-4.
This morning, Credit Suisse increased its price target on shares of Johnson & Johnson to $94 as growth from Invokana is expected to be better than originally expected.
Pfizer is one of the biopharmaceutical companies hardest hit by drugs losing patent exclusivity.
Recently, I came across Stryker on Eddy Elfenbein's excellent Crossing Wall Street blog.
This week's multi-billion dollar corporate bond offerings from Microsoft, CVS Caremark and Johnson & Johnson pushed the volume of US non-financial investment grade corporate debt to $438.0 billion for year-to-date 2013, a 6% increase compared to a year ago and the strongest year-to-date period on record.
The Wharton School, through its Initiative for Global Environmental Leadership , partnered with Johnson & Johnson to convene healthcare professionals and share best practices for measuring the value of sustainability initiatives in the healthcare field.
If you're vaguely familiar with my writings, you know that I usually proclaim to be a dividend growth investor or DGI.
Applications are now open for a new $8 million grant program designed to improve mental health services in Massachusetts.
Bayer AG, a global leader in life and material sciences, ranks as the world's number two consumer health company by sales.
Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
In a court filing by a patients attorney in West Virginia on December 2, Johnson & Johnson officials of J&J's Ethicon unit, makers of Gynecare Prolift implant, lost or disposed of potentially hundreds of thousands of documents over a decade even though they were ordered by executives to preserve them.
The firm currently has a $61.00 target price on the stock, up from their previous target price of $45.00.
Under the new agreement, USMI will begin shipping product to Chesapeake Surgical for distribution starting in 2014.
Aisling Capital is a private-equity firm. It makes investments in product acquisitions, positioning companies, follow-on financings, and industry consolidations.
Danish biotech company Genmab on Wednesday announced an expansion of its Duobody antibody technology collaboration with Janssen Biotech, a part of Johnson & Johnson.